Hammerman M R, Miller S B
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Pediatr. 1997 Jul;131(1 Pt 2):S17-9. doi: 10.1016/s0022-3476(97)70004-0.
Polypeptide growth factors regulate kidney development, growth, and function and participate in the repair processes after renal injury. The use of one or more growth factors as therapeutic agents in the settings of acute and chronic renal failure has been proposed. Insulin-like growth factor I (IGF-I) accelerates the restoration of kidney function and the normalization of structure and reduces mortality rates in animal models of acute renal injury. The mechanisms by which IGF-I acts in acute renal failure include stimulation of anabolism, maintenance of glomerular filtration, acceleration of tubular regeneration, and increased expression of ischemia-induced renal genes. It has been safely used in persons at risk of having acute renal failure and in patients with end-stage chronic renal failure, in whom it increases the glomerular filtration rate. Further studies to determine the role of IGF-I as a therapeutic agent for acute renal failure and its utility as a medical therapy for chronic renal insufficiency are required.
多肽生长因子调节肾脏的发育、生长和功能,并参与肾损伤后的修复过程。有人提出在急性和慢性肾衰竭的情况下使用一种或多种生长因子作为治疗剂。胰岛素样生长因子I(IGF-I)可加速急性肾损伤动物模型中肾功能的恢复和结构的正常化,并降低死亡率。IGF-I在急性肾衰竭中发挥作用的机制包括刺激合成代谢、维持肾小球滤过、加速肾小管再生以及增加缺血诱导的肾脏基因的表达。它已被安全地用于有急性肾衰竭风险的人和终末期慢性肾衰竭患者,可提高这些患者的肾小球滤过率。需要进一步研究以确定IGF-I作为急性肾衰竭治疗剂的作用及其作为慢性肾功能不全药物治疗的效用。